A novel PPAR alpha agonist ameliorates insulin resistance in dogs fed a high-fat diet

作者：Tsunoda Masaki; Kobayashi Naoki; Ide Tomohiro; Utsumi Mari; Nagasawa Michiaki; Murakami Koji^*

来源：American Journal of Physiology - Endocrinology And Metabolism, 2008, 294(5): E833-E840.

DOI：10.1152/ajpendo.00627.2007

• KRP-101
• obesity
• insulin resistance
• muscle lipid oxidation

Agonism of peroxisome proliferator-activated receptor (PPAR) alpha, a key regulator of lipid metabolism, leads to amelioration of lipid abnormalities in dyslipidemic patients. However, whether PPAR alpha agonism is an effective form of therapy for obesity-related insulin resistance associated with lipid abnormalities is unclear. The present study investigated the effects of a potent and subtype-selective PPAR alpha agonist, KRP-101, in a nonrodent insulin-resistant animal model under pair-fed conditions. Beagle dogs were fed a high-fat diet for 24 wk to induce insulin resistance. During the final 12 wk, 0.03 mg center dot kg(-1)center dot day(-1) KRP-101 (n = 5) or vehicle (n = 5) was administered orally once a day. KRP-101 administration resulted in a significantly lower weight of overall visceral fat, which is associated with increased adiponectin and decreased leptin in serum. KRP-101 administration improved hyperglycemia and hyperinsulinemia as well as dyslipidemia in dogs fed a high-fat diet. Oral glucose tolerance test showed that KRP-101 administration improved glucose intolerance. The KRP-101 group showed a markedly lower hepatic triglyceride concentration. Lipid oxidation was increased in the liver and skeletal muscles of the KRP-101 group. These findings in the dog model suggest that the use of potent and subtype-selective PPAR alpha agonists as a potentially relevant therapeutic approach to treat human insulin resistance associated with visceral obesity.

• 出版日期2008-5